Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
For patients with metastatic kidney cancer, we compared the survival time free from a second treatment line for different first-line treatment options. The results show that the time free from second-line treatment was longer when first-line treatment was with a combination of two immunotherapy drugs (ipilimumab and nivolumab) in comparison to other treatment options.
Authors
- Meredith M. Regan (ORCID: https://orcid.org/0000-0002-2428-6109)
- Naveen S. Basappa (ORCID: https://orcid.org/0000-0002-3163-9902)
- Aly‐Khan A. Lalani (ORCID: https://orcid.org/0000-0002-9907-9112)
- Connor Wells
- Ravindran Kanesvaran (ORCID: https://orcid.org/0000-0002-2351-881X)
- Vishal Navani (ORCID: https://orcid.org/0000-0002-6795-009X)
- Renée Maria Saliby (ORCID: https://orcid.org/0000-0002-9241-597X)
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Rana R. McKay (ORCID: https://orcid.org/0000-0002-0581-7963)
- Frede Donskov
- Jae‐Lyun Lee (ORCID: https://orcid.org/0000-0002-9420-7162)
- Kosuke null Takemura (ORCID: https://orcid.org/0000-0003-4321-6074)
- Wanling Xie (ORCID: https://orcid.org/0000-0001-5995-8000)
- Thomas Powles
- Megan Crumbaker (ORCID: https://orcid.org/0000-0001-7213-900X)
- Hedyeh Ebrahimi
- Christian Kollmannsberger (ORCID: https://orcid.org/0000-0002-6329-761X)
- Takeshi Yuasa (ORCID: https://orcid.org/0000-0002-8924-6730)
- Mehul Gupta
- Daniel Y.C. Heng
Institutions
- Ulsan College (KR)
- BC Cancer Agency (CA)
- Barts Health NHS Trust (GB)
- Asan Medical Center (KR)
- University of California San Diego (US)
- University of Ulsan (KR)
- Dana-Farber Cancer Institute (US)
- National Cancer Centre Singapore (SG)
Publication Details
- Journal
- European Urology Oncology
- Published
- 2024-12-31
- DOI
- https://doi.org/10.1016/j.euo.2024.12.011
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42